Skip to Content
Merck
  • Structure-activity relationships of anticancer ruthenium(II) complexes with substituted hydroxyquinolines.

Structure-activity relationships of anticancer ruthenium(II) complexes with substituted hydroxyquinolines.

European journal of medicinal chemistry (2018-07-29)
Dmytro Havrylyuk, Brock S Howerton, Leona Nease, Sean Parkin, David K Heidary, Edith C Glazer
ABSTRACT

8-Hydroxyquinolines (HQ), including clioquinol, possess cytotoxic properties and are widely used as ligands for metal-based anticancer drug research. The number and identity of substituents on the HQ can have a profound effect on activity for a variety of inorganic compounds. Ruthenium complexes of HQ exhibit radically improved potencies, and operate by a new, currently unknown, mechanism of action. To define structure-activity relationships (SAR), a family of 22 Ru(II) coordination complexes containing mono-, di- and tri-substituted hydroxyquinoline ligands were synthesized and their biological activity evaluated. The complexes exhibited promising cytotoxic activity against a cancer cell line, and the SAR data revealed the 2- and 7-positions as key sites for the incorporation of halogens to improve potency. The Ru(II) complexes potently inhibited translation, as demonstrated by an in-cell translation assay. The effects were seen at 2-15-fold higher concentrations than those required to observe cytotoxicity, suggesting that prevention of protein synthesis may be a primary, but not the exclusive mechanism for the observed cytotoxic activity.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
5,7-Dichloro-8-quinolinol, 99%
Sigma-Aldrich
5,7-Diiodo-8-hydroxyquinoline, 95%
Sigma-Aldrich
5,7-Dichloro-8-hydroxy-2-methylquinoline, 98%
Sigma-Aldrich
7-Bromo-8-hydroxyquinoline, 97%